DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRXGet Rating) in a report issued on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

DURECT Price Performance

DRRX opened at $0.49 on Monday. The stock’s 50 day simple moving average is $0.48 and its 200 day simple moving average is $0.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 7.83 and a quick ratio of 7.60. DURECT has a 1 year low of $0.36 and a 1 year high of $1.47. The firm has a market cap of $111.60 million, a price-to-earnings ratio of -3.06 and a beta of 1.47.

DURECT (NASDAQ:DRRXGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). DURECT had a negative return on equity of 60.89% and a negative net margin of 270.27%. The business had revenue of $1.92 million for the quarter, compared to analyst estimates of $2.43 million. During the same period last year, the company earned ($0.05) EPS. As a group, analysts predict that DURECT will post -0.19 earnings per share for the current year.

Insider Buying and Selling

In other DURECT news, Director Judith J. Robertson acquired 65,000 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were purchased at an average cost of $0.39 per share, for a total transaction of $25,350.00. Following the transaction, the director now owns 265,000 shares in the company, valued at $103,350. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have purchased a total of 186,911 shares of company stock worth $73,686 in the last ninety days. 5.20% of the stock is owned by insiders.

Institutional Investors Weigh In On DURECT

A number of large investors have recently made changes to their positions in DRRX. CM Management LLC grew its position in shares of DURECT by 20.9% in the 1st quarter. CM Management LLC now owns 3,535,732 shares of the specialty pharmaceutical company’s stock worth $2,369,000 after buying an additional 610,537 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of DURECT by 20.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,500,278 shares of the specialty pharmaceutical company’s stock worth $2,345,000 after buying an additional 588,848 shares during the last quarter. Beirne Wealth Consulting Services LLC grew its position in shares of DURECT by 11.3% in the 2nd quarter. Beirne Wealth Consulting Services LLC now owns 3,070,296 shares of the specialty pharmaceutical company’s stock worth $1,468,000 after buying an additional 310,625 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of DURECT in the 1st quarter worth approximately $53,000. Finally, Gagnon Securities LLC grew its position in shares of DURECT by 5.5% in the 4th quarter. Gagnon Securities LLC now owns 1,401,051 shares of the specialty pharmaceutical company’s stock worth $1,381,000 after buying an additional 73,647 shares during the last quarter. 50.60% of the stock is currently owned by institutional investors.

DURECT Company Profile

(Get Rating)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Read More

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.